Skip to main content
PMC home page
Molecular and Cellular Biology logoLink to Molecular and Cellular Biology
. 1997 Jul;17(7):4169–4177. doi: 10.1128/mcb.17.7.4169

Chimeras of the native form or achondroplasia mutant (G375C) of human fibroblast growth factor receptor 3 induce ligand-dependent differentiation of PC12 cells.

L M Thompson 1, S Raffioni 1, J J Wasmuth 1, R A Bradshaw 1
PMCID: PMC232270  PMID: 9199352

Abstract

Mutations in the gene for human fibroblast growth factor receptor 3 (hFGFR3) cause a variety of skeletal dysplasias, including the most common genetic form of dwarfism, achondroplasia (ACH). Evidence indicates that these phenotypes are not due to simple haploinsufficiency of FGFR3 but are more likely related to a role in negatively regulating skeletal growth. The effects of one of these mutations on FGFR3 signaling were examined by constructing chimeric receptors composed of the extracellular domain of human platelet-derived growth factor receptor beta (hPDGFR beta) and the transmembrane and intracellular domains of hFGFR3 or of an ACH (G375C) mutant. Following stable transfection in PC12 cells, which lack platelet-derived growth factor (PDGF) receptors, all clonal cell lines, with either type of chimera, showed strong neurite outgrowth in the presence of PDGF but not in its absence. Antiphosphotyrosine immunoblots showed ligand-dependent autophosphorylation, and both receptor types stimulated strong phosphorylation of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase, an event associated with the differentiative response of these cells. In addition, ligand-dependent phosphorylation of phospholipase Cgamma and Shc was also observed. All of these responses were comparable to those observed from ligand activation, such as by nerve growth factor, of the native PC12 cells used to prepare the stable transfectants. The cells with the chimera bearing the ACH mutation were more rapidly responsive to ligand with less sustained MAPK activation, indicative of a preactivated or primed condition and consistent with the view that these mutations weaken ligand control of FGFR3 function. However, the full effect of the mutation likely depends in part on structural features of the extracellular domain. Although FGFR3 has been suggested to act as a negative regulator of long-bone growth in chrondrocytes, it produces differentiative signals similar to those of FGFR1, to which only positive effects have been ascribed, in PC12 cells. Therefore, its regulatory effects on bone growth likely result from cellular contexts and not the induction of a unique FGFR3 signaling pathway.

Full Text

The Full Text of this article is available as a PDF (911.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adam M. A., Ramesh N., Miller A. D., Osborne W. R. Internal initiation of translation in retroviral vectors carrying picornavirus 5' nontranslated regions. J Virol. 1991 Sep;65(9):4985–4990. doi: 10.1128/jvi.65.9.4985-4990.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bellus G. A., Gaudenz K., Zackai E. H., Clarke L. A., Szabo J., Francomano C. A., Muenke M. Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromes. Nat Genet. 1996 Oct;14(2):174–176. doi: 10.1038/ng1096-174. [DOI] [PubMed] [Google Scholar]
  3. Bellus G. A., McIntosh I., Smith E. A., Aylsworth A. S., Kaitila I., Horton W. A., Greenhaw G. A., Hecht J. T., Francomano C. A. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat Genet. 1995 Jul;10(3):357–359. doi: 10.1038/ng0795-357. [DOI] [PubMed] [Google Scholar]
  4. Bonaventure J., Rousseau F., Legeai-Mallet L., Le Merrer M., Munnich A., Maroteaux P. Common mutations in the fibroblast growth factor receptor 3 (FGFR 3) gene account for achondroplasia, hypochondroplasia, and thanatophoric dwarfism. Am J Med Genet. 1996 May 3;63(1):148–154. doi: 10.1002/(SICI)1096-8628(19960503)63:1<148::AID-AJMG26>3.0.CO;2-N. [DOI] [PubMed] [Google Scholar]
  5. Burgess W. H., Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem. 1989;58:575–606. doi: 10.1146/annurev.bi.58.070189.003043. [DOI] [PubMed] [Google Scholar]
  6. Chellaiah A. T., McEwen D. G., Werner S., Xu J., Ornitz D. M. Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1. J Biol Chem. 1994 Apr 15;269(15):11620–11627. [PubMed] [Google Scholar]
  7. Chen C., Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol. 1987 Aug;7(8):2745–2752. doi: 10.1128/mcb.7.8.2745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Claesson-Welsh L., Hammacher A., Westermark B., Heldin C. H., Nistér M. Identification and structural analysis of the A type receptor for platelet-derived growth factor. Similarities with the B type receptor. J Biol Chem. 1989 Jan 25;264(3):1742–1747. [PubMed] [Google Scholar]
  9. Colvin J. S., Bohne B. A., Harding G. W., McEwen D. G., Ornitz D. M. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet. 1996 Apr;12(4):390–397. doi: 10.1038/ng0496-390. [DOI] [PubMed] [Google Scholar]
  10. Deng C., Wynshaw-Boris A., Zhou F., Kuo A., Leder P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell. 1996 Mar 22;84(6):911–921. doi: 10.1016/s0092-8674(00)81069-7. [DOI] [PubMed] [Google Scholar]
  11. Green P. J., Walsh F. S., Doherty P. Promiscuity of fibroblast growth factor receptors. Bioessays. 1996 Aug;18(8):639–646. doi: 10.1002/bies.950180807. [DOI] [PubMed] [Google Scholar]
  12. Ikegawa S., Fukushima Y., Isomura M., Takada F., Nakamura Y. Mutations of the fibroblast growth factor receptor-3 gene in one familial and six sporadic cases of achondroplasia in Japanese patients. Hum Genet. 1995 Sep;96(3):309–311. doi: 10.1007/BF00210413. [DOI] [PubMed] [Google Scholar]
  13. Jaye M., Schlessinger J., Dionne C. A. Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim Biophys Acta. 1992 Jun 10;1135(2):185–199. doi: 10.1016/0167-4889(92)90136-y. [DOI] [PubMed] [Google Scholar]
  14. Johnson D. E., Williams L. T. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res. 1993;60:1–41. doi: 10.1016/s0065-230x(08)60821-0. [DOI] [PubMed] [Google Scholar]
  15. Keegan K., Johnson D. E., Williams L. T., Hayman M. J. Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3. Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1095–1099. doi: 10.1073/pnas.88.4.1095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lin H. Y., Xu J., Ornitz D. M., Halegoua S., Hayman M. J. The fibroblast growth factor receptor-1 is necessary for the induction of neurite outgrowth in PC12 cells by aFGF. J Neurosci. 1996 Aug 1;16(15):4579–4587. doi: 10.1523/JNEUROSCI.16-15-04579.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Markowitz D., Goff S., Bank A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol. 1988 Apr;62(4):1120–1124. doi: 10.1128/jvi.62.4.1120-1124.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Meyers G. A., Day D., Goldberg R., Daentl D. L., Przylepa K. A., Abrams L. J., Graham J. M., Jr, Feingold M., Moeschler J. B., Rawnsley E. FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and Pfeiffer syndromes: evidence for missense changes, insertions, and a deletion due to alternative RNA splicing. Am J Hum Genet. 1996 Mar;58(3):491–498. [PMC free article] [PubMed] [Google Scholar]
  19. Meyers G. A., Orlow S. J., Munro I. R., Przylepa K. A., Jabs E. W. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet. 1995 Dec;11(4):462–464. doi: 10.1038/ng1295-462. [DOI] [PubMed] [Google Scholar]
  20. Muenke M., Schell U. Fibroblast-growth-factor receptor mutations in human skeletal disorders. Trends Genet. 1995 Aug;11(8):308–313. doi: 10.1016/s0168-9525(00)89088-5. [DOI] [PubMed] [Google Scholar]
  21. Mulvihill J. J. Craniofacial syndromes: no such thing as a single gene disease. Nat Genet. 1995 Feb;9(2):101–103. doi: 10.1038/ng0295-101. [DOI] [PubMed] [Google Scholar]
  22. Naski M. C., Wang Q., Xu J., Ornitz D. M. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet. 1996 Jun;13(2):233–237. doi: 10.1038/ng0696-233. [DOI] [PubMed] [Google Scholar]
  23. Obermeier A., Bradshaw R. A., Seedorf K., Choidas A., Schlessinger J., Ullrich A. Neuronal differentiation signals are controlled by nerve growth factor receptor/Trk binding sites for SHC and PLC gamma. EMBO J. 1994 Apr 1;13(7):1585–1590. doi: 10.1002/j.1460-2075.1994.tb06421.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Obermeier A., Lammers R., Wiesmüller K. H., Jung G., Schlessinger J., Ullrich A. Identification of Trk binding sites for SHC and phosphatidylinositol 3'-kinase and formation of a multimeric signaling complex. J Biol Chem. 1993 Nov 5;268(31):22963–22966. [PubMed] [Google Scholar]
  25. Peters K., Ornitz D., Werner S., Williams L. Unique expression pattern of the FGF receptor 3 gene during mouse organogenesis. Dev Biol. 1993 Feb;155(2):423–430. doi: 10.1006/dbio.1993.1040. [DOI] [PubMed] [Google Scholar]
  26. Przylepa K. A., Paznekas W., Zhang M., Golabi M., Bias W., Bamshad M. J., Carey J. C., Hall B. D., Stevenson R., Orlow S. Fibroblast growth factor receptor 2 mutations in Beare-Stevenson cutis gyrata syndrome. Nat Genet. 1996 Aug;13(4):492–494. doi: 10.1038/ng0896-492. [DOI] [PubMed] [Google Scholar]
  27. Rousseau F., Bonaventure J., Legeai-Mallet L., Pelet A., Rozet J. M., Maroteaux P., Le Merrer M., Munnich A. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature. 1994 Sep 15;371(6494):252–254. doi: 10.1038/371252a0. [DOI] [PubMed] [Google Scholar]
  28. Rousseau F., el Ghouzzi V., Delezoide A. L., Legeai-Mallet L., Le Merrer M., Munnich A., Bonaventure J. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1). Hum Mol Genet. 1996 Apr;5(4):509–512. doi: 10.1093/hmg/5.4.509. [DOI] [PubMed] [Google Scholar]
  29. Rönnstrand L., Terracio L., Claesson-Welsh L., Heldin C. H., Rubin K. Characterization of two monoclonal antibodies reactive with the external domain of the platelet-derived growth factor receptor. J Biol Chem. 1988 Jul 25;263(21):10429–10435. [PubMed] [Google Scholar]
  30. Sanger F., Nicklen S., Coulson A. R. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463–5467. doi: 10.1073/pnas.74.12.5463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Schlessinger J., Ullrich A. Growth factor signaling by receptor tyrosine kinases. Neuron. 1992 Sep;9(3):383–391. doi: 10.1016/0896-6273(92)90177-f. [DOI] [PubMed] [Google Scholar]
  32. Shiang R., Thompson L. M., Zhu Y. Z., Church D. M., Fielder T. J., Bocian M., Winokur S. T., Wasmuth J. J. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell. 1994 Jul 29;78(2):335–342. doi: 10.1016/0092-8674(94)90302-6. [DOI] [PubMed] [Google Scholar]
  33. Spivak-Kroizman T., Mohammadi M., Hu P., Jaye M., Schlessinger J., Lax I. Point mutation in the fibroblast growth factor receptor eliminates phosphatidylinositol hydrolysis without affecting neuronal differentiation of PC12 cells. J Biol Chem. 1994 May 20;269(20):14419–14423. [PubMed] [Google Scholar]
  34. Sternberg M. J., Gullick W. J. Neu receptor dimerization. Nature. 1989 Jun 22;339(6226):587–587. doi: 10.1038/339587a0. [DOI] [PubMed] [Google Scholar]
  35. Superti-Furga A., Eich G., Bucher H. U., Wisser J., Giedion A., Gitzelmann R., Steinmann B. A glycine 375-to-cysteine substitution in the transmembrane domain of the fibroblast growth factor receptor-3 in a newborn with achondroplasia. Eur J Pediatr. 1995 Mar;154(3):215–219. doi: 10.1007/BF01954274. [DOI] [PubMed] [Google Scholar]
  36. Tavormina P. L., Rimoin D. L., Cohn D. H., Zhu Y. Z., Shiang R., Wasmuth J. J. Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. Hum Mol Genet. 1995 Nov;4(11):2175–2177. doi: 10.1093/hmg/4.11.2175. [DOI] [PubMed] [Google Scholar]
  37. Tavormina P. L., Shiang R., Thompson L. M., Zhu Y. Z., Wilkin D. J., Lachman R. S., Wilcox W. R., Rimoin D. L., Cohn D. H., Wasmuth J. J. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet. 1995 Mar;9(3):321–328. doi: 10.1038/ng0395-321. [DOI] [PubMed] [Google Scholar]
  38. Thompson L. M., Plummer S., Schalling M., Altherr M. R., Gusella J. F., Housman D. E., Wasmuth J. J. A gene encoding a fibroblast growth factor receptor isolated from the Huntington disease gene region of human chromosome 4. Genomics. 1991 Dec;11(4):1133–1142. doi: 10.1016/0888-7543(91)90041-c. [DOI] [PubMed] [Google Scholar]
  39. Tischler A. S., Greene L. A. Nerve growth factor-induced process formation by cultured rat pheochromocytoma cells. Nature. 1975 Nov 27;258(5533):341–342. doi: 10.1038/258341a0. [DOI] [PubMed] [Google Scholar]
  40. Webster M. K., Donoghue D. J. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J. 1996 Feb 1;15(3):520–527. [PMC free article] [PubMed] [Google Scholar]
  41. Weiner D. B., Liu J., Cohen J. A., Williams W. V., Greene M. I. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature. 1989 May 18;339(6221):230–231. doi: 10.1038/339230a0. [DOI] [PubMed] [Google Scholar]
  42. Williams L. T. Signal transduction by the platelet-derived growth factor receptor. Science. 1989 Mar 24;243(4898):1564–1570. doi: 10.1126/science.2538922. [DOI] [PubMed] [Google Scholar]
  43. Wu Y. Y., Bradshaw R. A. Effect of nerve growth factor and fibroblast growth factor on PC12 cells: inhibition by orthovanadate. J Cell Biol. 1993 Apr;121(2):409–422. doi: 10.1083/jcb.121.2.409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Wu Y. Y., Bradshaw R. A. Induction of neurite outgrowth by interleukin-6 is accompanied by activation of Stat3 signaling pathway in a variant PC12 cell (E2) line. J Biol Chem. 1996 May 31;271(22):13023–13032. doi: 10.1074/jbc.271.22.13023. [DOI] [PubMed] [Google Scholar]
  45. Wu Y. Y., Bradshaw R. A. Synergistic induction of neurite outgrowth by nerve growth factor or epidermal growth factor and interleukin-6 in PC12 cells. J Biol Chem. 1996 May 31;271(22):13033–13039. doi: 10.1074/jbc.271.22.13033. [DOI] [PubMed] [Google Scholar]

Articles from Molecular and Cellular Biology are provided here courtesy of Taylor & Francis

RESOURCES